Pfizer inks Blackstone Life Sciences funding deal for berobenatide, a late-stage GLP-1 obesity program

Pfizer has secured up to $1.5 billion in development funding through a partnership with Blackstone Life Sciences to support berobenatide, the company’s investigational GLP-1 treatment being developed for obesity, according to a report posted on Yahoo Finance.

Under the arrangement, Blackstone Life Sciences will co-fund late-stage development activities for berobenatide, with Pfizer continuing to drive the program. GLP-1 drugs (glucagon-like peptide-1) work by targeting hormone pathways involved in appetite and glucose regulation, and they are a major focus in obesity and metabolic disease drug development.

The deal is described as providing “up to” $1.5 billion in development funding, suggesting the full amount is conditional on future progress and/or milestones rather than guaranteed cash from day one. Beyond that ceiling, the cited report does not spell out the payment structure, timing, or whether funding is linked to specific clinical events.

Pfizer, which has increasingly relied on pipeline prioritization to manage development costs across multiple therapeutic areas, framed the move as support for berobenatide’s late-stage push. The report characterizes the funding as part of an effort to advance the candidate through later development stages, which typically involve the largest incremental clinical spending.

For Blackstone Life Sciences, the partnership fits a broader pattern in life sciences investing, in which large asset managers and private capital groups provide staged funding to help translate promising candidates into late-stage trials and potential commercialization. By tying capital to development progress, these structures aim to reduce risk compared with fully upfront funding.